{"id":"W2947993621","doi":"10.1200/jco.2019.37.15_suppl.tps5603","title":"ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Carboplatin; Oncology; Tolerability; Internal medicine; Olaparib; BRCA mutation; Debulking; Placebo; Chemotherapy; Gynecology; Surgery; Cancer; Adverse effect; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002463214,0.002070686,0.002542207,0.0005466906,0.0005921772,0.001297763,0.001524789,0.00229604,0.01225407],"category_scores_gemma":[0.001537127,0.000942677,0.001516499,0.0005312384,0.001262086,0.001529893,0.0004385514,0.004506636,0.001691649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00109929,"about_ca_system_score_gemma":0.002572859,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001480762,"about_ca_topic_score_gemma":0.004589795,"domain_scores_codex":[0.9995003,0.0002329966,0.00002588576,0.0001003754,0.00004606379,0.00009433378],"domain_scores_gemma":[0.9992062,0.0001381152,0.0001962495,0.00005232358,0.00005241438,0.0003545728],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9461875,0.02057069,0.0005881772,0.00173897,0.0008875529,0.00004446718,0.00007231715,0.0002794665,0.005734952,0.0003013591,0.003361497,0.02023298],"study_design_scores_gemma":[0.9658914,0.03156281,0.0008396787,0.00003840419,0.0002041123,0.00002306709,0.00001372508,0.0001824531,0.0002803687,0.00009570338,0.0008574796,0.00001080127],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.930265,0.01409986,0.002117976,0.002421708,0.001635031,0.03302143,0.008453481,0.0006624993,0.007323013],"genre_scores_gemma":[0.9325757,0.007965175,0.005947301,0.004972168,0.0006679213,0.03224275,0.005703529,0.0001355322,0.009789978],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01225407,"threshold_uncertainty_score":0.04099393,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07951074915557566,"score_gpt":0.4580442638333461,"score_spread":0.3785335146777704,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}